Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
Efficacy and risks of drug holiday in the management of medication-related osteonecrosis of the jaw in cancer patients: a single-center retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hata Hironobu, Imamachi Kenji, Yoshikawa Kazuhito, Kamaguchi Mayumi, Osanai Toshihisa, Matsuzaka Masashi, Watanabe Kenichi, Tomioka Nobumoto, Harabayashi Toru, Fujimoto Katsuya, Oizumi Satoshi, Ueda Michihiro, Hiraga Hiroaki, Miyamoto Ikuya
Аннотация
PURPOSE: Discontinuing bone-modifying agents (BMAs) during management of medication-related osteonecrosis of the jaw (MRONJ) remains controversial. This retrospective study evaluates the impact and potential risks of BMA drug holidays in cancer patients with MRONJ.
METHODS: We retrospectively classified 156 cancer patients with MRONJ into four groups: BMA withdrawal with conservative therapy (WC, n = 40), withdrawal with surgical therapy (WS, n = 63), non-withdrawal with conservative therapy (nWC, n = 30), and non-withdrawal with surgical therapy (nWS, n = 23). In the WS group, surgery was performed after radiographic confirmation of bone sequestration following BMA discontinuation. Healing rates and skeletal-related events (SREs) incidence were analyzed.
RESULTS: The healing rates from MRONJ onset were 94.7% in the WS group, 53.6% in the nWS group, 25.5% in the WC group, and 0% in the nWC group. Among surgical patients, the healing rate from the time of surgery was significantly higher in the WS group (92.3%) than in the nWS group (47.8%) (hazard ratio = 3.23, p < 0.05). The incidence of SREs was 52.3% in the WC group, 15.8% in the WS group, 16.7% in the nWS group, and 4.2% in the nWC group. The WC group showed a significantly higher incidence of SREs compared with the WS and nWS groups.
CONCLUSION: A therapeutic strategy involving planned BMA discontinuation followed by delayed surgical intervention after radiographic confirmation of sequestrum formation, may be associated with improved healing outcomes. This approach does not appear to increase the incidence of SREs, particularly when BMA therapy is appropriately resumed after successful surgical healing.
METHODS: We retrospectively classified 156 cancer patients with MRONJ into four groups: BMA withdrawal with conservative therapy (WC, n = 40), withdrawal with surgical therapy (WS, n = 63), non-withdrawal with conservative therapy (nWC, n = 30), and non-withdrawal with surgical therapy (nWS, n = 23). In the WS group, surgery was performed after radiographic confirmation of bone sequestration following BMA discontinuation. Healing rates and skeletal-related events (SREs) incidence were analyzed.
RESULTS: The healing rates from MRONJ onset were 94.7% in the WS group, 53.6% in the nWS group, 25.5% in the WC group, and 0% in the nWC group. Among surgical patients, the healing rate from the time of surgery was significantly higher in the WS group (92.3%) than in the nWS group (47.8%) (hazard ratio = 3.23, p < 0.05). The incidence of SREs was 52.3% in the WC group, 15.8% in the WS group, 16.7% in the nWS group, and 4.2% in the nWC group. The WC group showed a significantly higher incidence of SREs compared with the WS and nWS groups.
CONCLUSION: A therapeutic strategy involving planned BMA discontinuation followed by delayed surgical intervention after radiographic confirmation of sequestrum formation, may be associated with improved healing outcomes. This approach does not appear to increase the incidence of SREs, particularly when BMA therapy is appropriately resumed after successful surgical healing.